Restasis (Dry Eye Syndrome) - Analysis and Forecasts to 2022 New Report
Restasis (Dry Eye Syndrome) - Analysis and Forecasts to 2022 provides Restasis sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2022). The report also includes information on Dry Eye Syndrome. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured...
View full press release